Sequencing success

Since its launch in 2011, Ion AmpliSeq targeted sequencing technology has seen broad global adoption and resulted in the publication of over 140 peer reviewed publications across a broad range of applications. Applications span such studies as investigating phenovariance in mice1, assessing gene copy number alterations2, and defining genetic changes associated with lung cancer3 research.

Researchers are not only using Ion AmpliSeq technology for samples where available sample quantity and quality are not limiting, such as cell culture or fresh-frozen tissues, but also seeing tremendous success with challenging sample types, such as formalin-fixed paraffin-embedded (FFPE) tissue, archived samples from fine needle aspirates , and circulating cell-free DNA (cfDNA) extracted from blood.

Wang et al. (2015) Proc. Natl. Acad. Sci. 112: E440-E449.

Grasso et al. (2014) J. Mol. Diagn. 17: 53-63.

de Bruin et al. (2014) Science 346: 251-256.

“We’ve created four custom Ion AmpliSeq panels, and all of them are performing extremely well on FFPE-derived DNA.”